Search Results - "Lin, Yuehui"
-
1
PB1738: OBSERVATION OF THERAPEUTIC EFFECT OF BLINATUMOMAB SALVAGE TREATMENT ON B – ALL WITH INVALID OR RECURRENT CART
Published in HemaSphere (08-08-2023)Get full text
Journal Article -
2
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
Published in Leukemia (01-12-2019)“…Despite worldwide promising clinical outcome of CD19 CAR-T therapy, relapse after this therapy is associated with poor prognosis and has become an urgent…”
Get full text
Journal Article -
3
Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia
Published in Blood cancer journal (New York) (06-02-2020)Get full text
Journal Article -
4
A study on the formula of fundamental period of high-rise shear wall structures based on ambient vibration testing
Published in Structures (Oxford) (01-06-2024)“…The dynamic performance test was conducted on 50 high-rise shear wall structures with heights ranging from 30 to 80 m in the high-risk seismic region of…”
Get full text
Journal Article -
5
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Published in BMC cancer (12-04-2022)“…For CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) after treatment with murine CD19 (mCD19) CAR-T, the reinfusion of mCD19…”
Get full text
Journal Article -
6
Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy
Published in Frontiers in oncology (21-09-2022)“…Chimeric antigen receptor (CAR)-T cell therapy provides an effective salvage treatment for relapsed/refractory multiple myeloma (RRMM) patients. End-stage RRMM…”
Get full text
Journal Article -
7
CAR‐T therapy as a consolidation in remission B‐ALL patients with poor prognosis
Published in Cancer reports (01-10-2022)“…Background To date, almost all studies regarding chimeric antigen receptor (CAR)‐T cell therapy for B‐cell acute lymphoblastic leukemia (B‐ALL) were performed…”
Get full text
Journal Article -
8
Efficacy and safety of high-dose intramuscular vitamin D2 injection in type 2 diabetes mellitus with distal symmetric polyneuropathy combined with vitamin D insufficiency: study protocol for a multicenter, randomized, double-blinded, and placebo-controlled trial
Published in Frontiers in endocrinology (Lausanne) (07-07-2023)“…Background Distal symmetric polyneuropathy (DSPN) is the most common chronic complication of type 2 diabetes mellitus (T2DM). DSPN may lead to more serious…”
Get full text
Journal Article -
9
P387: THE TREATMENT RESPONSE OF A TWO‐DOSE REGIMEN OF DOSE‐ADJUSTED INOTUZUMAB IN RELAPSED/REFRACTORY B‐ALL
Published in HemaSphere (08-08-2023)Get full text
Journal Article -
10
Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL
Published in Molecular therapy. Methods & clinical development (10-12-2021)“…Our previous clinical study achieved complete remission (CR) rates of >90% following chimeric antigen receptor T cells targeting CD19 (CART19) treatment of…”
Get full text
Journal Article -
11
The Efficacy and Safety of Olverembatinib Combined with Monoclonal Antibodies As Salvage Therapy for RR B ALL with ABL1 Fusion Gene Positive
Published in Blood (02-11-2023)“…Background: B cell acute Lymphoblastic Leukemia (B ALL) with ABL1 fusion gene(FG) positive(ABL1+B ALL) is classified as Ph or Ph like ALL and has a poor…”
Get full text
Journal Article -
12
Clinical Implications of Germline Predisposition Gene Variants in Patients with Refractory or Relapsed B Acute Lymphoblastic Leukemia
Published in Blood (02-11-2023)“…Objectives:Gene variants are important factors in prognosis of the patients with hematological malignancies. In current study, our team investigate the…”
Get full text
Journal Article -
13
Combination of CD19 and CD22 CAR‐T cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantation
Published in American journal of hematology (01-06-2021)“…The prognosis of relapsed acute lymphoblastic leukemia (ALL) after allogeneic transplantation is dismal when treated with conventional approaches. While…”
Get full text
Journal Article -
14
A Novel t(9;22;11) Translocation Variant Involving 11q23 in a Patient with Chronic Myeloid Leukemia
Published in Blood (05-11-2020)“…Background:The progression of Philadelphia chromosome positive chronic myeloid leukemia (CML) is frequently accompanied by cytogenetic evolution, commonly…”
Get full text
Journal Article -
15
Sequential CD19- and CD22-CART Cell Therapies for Relapsed B-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
Published in Blood (29-11-2018)“…With traditional therapies, the prognosis of relapsed acute lymphoblastic leukemia (ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)…”
Get full text
Journal Article -
16
Corticosteroids Do Not Influence the Efficacy and Kinetics of CAR-T Cells for B-Cell Acute Lymphoblastic Leukemia
Published in Blood (13-11-2019)“…▪ Cytokine release syndrome (CRS) is the most prominent and potentially life-threatening toxicity caused by chimeric antigen receptor (CAR) T cell therapy,…”
Get full text
Journal Article -
17
Efficacy and safety of high-dose intramuscular vitamin D 2 injection in type 2 diabetes mellitus with distal symmetric polyneuropathy combined with vitamin D insufficiency: study protocol for a multicenter, randomized, double-blinded, and placebo-controlled trial
Published in Frontiers in endocrinology (Lausanne) (07-07-2023)“…Distal symmetric polyneuropathy (DSPN) is the most common chronic complication of type 2 diabetes mellitus (T2DM). DSPN may lead to more serious complications,…”
Get full text
Journal Article -
18
Leukemia Burden in Peripheral Blood Has Negative Impact on CD19-CART Cell Culture and Its Clinical Efficacy in Patients with Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia
Published in Blood (13-11-2019)“…Introduction: Recently, chimeric antigen receptor (CAR) T-cell (CART) targeting CD19 has resulted in high complete remission (CR) rate in patients with…”
Get full text
Journal Article -
19
Five-year Outcome of CD19 Combined With CD22 CAR-T Cell Therapy in Patients With B-ALL Relapsed After Allo-transplantation
Published in European medical journal. Hematology (25-07-2024)Get full text
Journal Article -
20
UNC13D G863D as a genetic predisposition factor of lymphoma and a founder mutation in Chinese
Published in Journal of clinical oncology (20-05-2016)“…Abstract only…”
Get full text
Journal Article